Alladapt’s allergy treatment receives FDA fast track designation
ADP101 is an oral immunotherapy to treat multi-food and single-food allergies
Read More
Tag: Alladapt Immunotherapeutics
- Exdensur approved in EU for severe asthma and CRSwNP
- Axol Bioscience acquires Newcells Biotech ophthalmology unit
- Nuclera and leadXpro partner to accelerate structure‑based drug design
- Lundbeck reports positive phase 2b results for migraine prevention drug
- European life sciences coalition launched to boost investment ecosystem
